CDC ENTEBBE

Opioid overdoses in Texas surged, with Austin-Travis County EMS responding to 75 cases in days, including 50 in 24 hours. A fentanyl vaccine, under development by University of Houston researchers, aims to prevent addiction by blocking the drug from reaching the brain. Clinical trials are set to begin in 2025, though FDA approval and public availability could take 5-10 years. Free Narcan kits are available in Austin to combat overdoses.

Faruqi & Faruqi, LLP's James (Josh) Wilson encourages investors who suffered losses exceeding $100,000 in Moderna between January 18, 2023, and June 25, 2024, to contact him directly to discuss their options. The firm is investigating potential claims against Moderna and reminds investors of the October 8, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The complaint alleges Moderna and its executives violated federal securities laws by making false and/or misleading statements regarding mRNA-1345's efficacy.

A new Parkinson’s drug, Crexont, reduces symptoms for 1.5 hours longer than current medications with fewer daily doses, designed by Dr. Robert A. Hauser. The 13-week study involving 630 patients found it more effective, potentially extending relief from tremors, stiffness, and speech difficulties. The drug’s slow-release mechanism allows for longer symptom prevention, improving quality of life for Parkinson’s patients.

FDA approves new Pfizer and Moderna COVID-19 vaccines for fall, targeting KP.2 variant. Symptoms remain similar to previous variants, with high risk of complications. mRNA technology promotes immune response, differing from traditional vaccines. CDC recommends updated vaccine for all Americans six months and older. Limited vaccine supply available for uninsured and underinsured patients.

FDA approved updated COVID-19 vaccines targeting Omicron variants JN.1 and KP.2 for ages 12+, with mRNA vaccines by Moderna and Pfizer for ages 6 months+. CDC recommends vaccination for everyone 6 months+, emphasizing importance for high-risk groups. Timing and doses depend on vaccination status. JN.1, KP.2, KP.3, and KP.3.1.1 are circulating variants. Pharmacies like CVS and Kroger offer the vaccines.

Crestone announces positive Phase 2 trial results for CRS3123 in treating C. difficile infections, showing high clinical cure rates, low recurrence, and safety. NIAID funds $4.5 million for further studies.

Crestone announces positive Phase 2 results for CRS3123 in treating C. difficile infections (CDI), showing high clinical cure rates and lower recurrence compared to vancomycin. CRS3123, a novel drug, maintains gut microbiota, addressing urgent need for effective CDI therapy.

September 1 marked the beginning of Suicide Prevention Awareness Month. For the veterinary profession, the suicide rate is high. This week on dvm360.com: clinical trials for canine cardiac tumors, a wellbeing guide for healthcare workers, Boehringer Ingelheim's acquisition of Saiba Animal Health, a podcast on suicide awareness, and updates on veterinary practices in Australia.

Positive immunogenicity and safety data from VLA15-221 Phase 2 study after second booster dose of Lyme disease vaccine candidate VLA15, showing strong immune response and favorable safety profile across all age groups.

First U.S. cluster of human bird flu cases detected at Colorado poultry facilities; 9 workers experienced mild symptoms from contact with infected poultry, with no human-to-human transmission.